Vera Therapeutics, Inc.
US ˙ NasdaqGM ˙ US92337R1014

SecurityVERA / Vera Therapeutics, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership278,765 shares
Latest Disclosed Value $ 11,214,716
Dimensional Fund Advisors Lp reports 20.78% decrease in ownership of VERA / Vera Therapeutics, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 278,765 shares of Vera Therapeutics, Inc. (US:VERA) valued at $11,214,716 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 351,886 shares of Vera Therapeutics, Inc.. This represents a change in shares of -20.78% during the quarter. The current value of the position is $8,716,982 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F VERA THERAPEUTICS CL A 92337R101 278,765 -73,121 -20.78 11,215 -37.07 0.0005
2026-02-12 2025-12-31 13F VERA THERAPEUTICS CL A 92337R101 351,886 -8,446 -2.34 17,820 70.17 0.0037
2025-11-12 2025-09-30 13F VERA THERAPEUTICS CL A 92337R101 360,332 206,652 134.47 10,471 189.25 0.0022
2025-08-12 2025-06-30 13F VERA THERAPEUTICS CL A 92337R101 153,680 139,912 1,016.21 3,621 996.97 0.0008
2025-05-13 2025-03-31 13F VERA THERAPEUTICS CL A 92337R101 13,768 -2,064 -13.04 331 -50.67 0.0001
2025-02-13 2024-12-31 13F VERA THERAPEUTICS CL A 92337R101 15,832 -1,900 -10.72 670 -14.56 0.0002
2024-11-07 2024-09-30 13F VERA THERAPEUTICS CL A 92337R101 17,732 0 0.00 784 22.15 0.0002
2024-08-09 2024-06-30 13F VERA THERAPEUTICS CL A 92337R101 17,732 0 0.00 642 -16.10 0.0002
2024-05-10 2024-03-31 13F VERA THERAPEUTICS CL A 92337R101 17,732 -33,190 -65.18 765 -2.43 0.0002
2024-02-07 2023-12-31 13F VERA THERAPEUTICS CL A 92337R101 50,922 50,922 783 0.0002
2023-05-12 2023-03-31 13F VERA THERAPEUTICS CL A 92337R101 0 -11,498 -100.00 0 0.0000
2023-02-09 2022-12-31 13F VERA THERAPEUTICS CL A 92337R101 11,498 11,498 0 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.